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Background:  Our study group established “3H care” in 2002. The meaning of “3H care” attain and maintain adequate controls 
over hypertension, hyperlipidemia, and hyperglycemia in type 2 diabetic patients. This study evaluated the achievement of target 
goals after one year or more of “3H care” by specialists in our diabetic clinic. 
Methods:  This was a retrospective study of 200 type 2 diabetic patients who received “3H care” for one year or more in our dia-
betic clinic. We evaluated achievement of target goals for metabolic controls as suggested by the American Diabetes Association.
Results:  Overall, 200 type 2 diabetes patients were enrolled, of whom 106 were males (53%) and 94 were females (47%). After 
one year of “3H care,” the mean HbA1c was 7.2±1.5% and the percentage of patients achieving glycemic control (HbA1c <7%) 
was 51.8%. However only 32.2% of hypertensive patients achieved the recommended target. After one year of “3H care,” the per-
centages of those who achieved the target value for dyslipidemia were 80.0% for total cholesterol, 66.3% for low density lipopro-
tein cholesterol, 57.9% for triglyceride, and 51.8% for high density lipoprotein cholesterol. The percentage that achieved all three 
targets level was only 4.4% after one year and 14.8% after two years. 
Conclusion:  The results of this study demonstrate that only a minor proportion of patients with type 2 diabetes achieved the 
recommended goals despite the implementation of “3H care.” It is our suggestion that better treatment strategies and methods 
should be used to control hypertension, hyperlipidemia and hyperglycemia.
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INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and 
mortality in diabetic patients, and among risk factors of car-
diovascular disease, diabetes is considered to be comparable to 
cardiovascular disease [1-6]. One large-scale prospective study 
on diabetes, the UK Prospective Diabetes Study (UKPDS), re-
ported that aggressive blood glucose control resulted in a de-
crease in microvascular complications, and though macrovas-
cular complications were not significantly reduced and showed 
that the prevention of cardiovascular disease through blood 
glucose control alone was insufficient [7-9]. Additionally, in 
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The Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) and The Action in Diabetes and Vascular Disease 
(ADVANCE) studies, strict blood glucose control reduced the 
incidences of microvascular complications, particularly dia-
betic nephropathy. Although this reduction was significant, 
and reduces the risk of cardiovascular disease, we concluded 
that there were relatively fewer contributing risk factors of car-
diovascular disease [10,11]. Steno-2 study results showed that 
the risk of microvascular complications and macrovascular 
complications can be reduced through integrated diabetes 
management [12]. When the results of the above study were 
summarized, the prevention of diabetic complications was 
shown to require integrated management that maintained car-
diometabolic risk factors such as dyslipidemia and hyperten-
sion, in addition to fundamental blood glucose management.
  Starting in 2002, our research group established the “3H care” 
concept in order to ideally manage hypertension, hyperlipid-
emia, and hyperglycemia in type 2 diabetic patients. Based on 
these concepts, the accompaniment of hypertension and dys-
lipidemia with the diagnosis of diabetes was confirmed. In ad-
dition, when hypertension and dyslipidemia existed in combi-
nation, combination that were treated equally hyperglycemia 
maintenance, patient education were perfomed, and necessary 
drugs were administered. During follow-up, the two associat-
ed conditions were managed to hyperglycemia identically. The 
importance of managing the aforementioned risk factors is al-
ready known, and it has been reported that the actual treat-
ment of individual risk factors does not result in the satisfacto-
ry achievement of target goals [13-17]. Our research group 
performed “3H care” on type 2 diabetic patients for one year, 
and analyzed blood glucose, blood pressure, and the goal lipid 
levels at the end of the study period. Additionally, to analyze 
patients who were tracked for two years, a performance evalu-
ation of 3H care was performed, from which it was determined 
that additional data to complement the maintenance method 
is required. It has been reported that the prevalence of meta-
bolic syndrome is high in type 2 diabetic patients, and type 2 
diabetes in combination with metabolic syndrome is known to 
increase mortality [18-20]. In this study, the prevalence of 
metabolic syndrome was investigated. This study was not 
based on specifically established guidelines or algorithms, and 
two endocrinology specialists performed treatment based on 
their own discretion and the clinical circumstances of each in-
dividual patient.
METHODS
Objective
This study was performed for three years from September 1, 
2004 to August 8, 2007 at a university hospital diabetes center. 
The patients who were registered as having type 2 diabetes and 
excluding those with chronic renal failure, malignant tumors, 
1,892 participants visited the outpatient clinic and received 
medical care for one year. During the one year follow-up peri-
od with the applicable patients at least three outpatient visits 
were performed, during which blood pressure, HbA1c, lipid 
levels, and weight were measured. A total of 200 patients were 
analyzed (106 men, 94 women). All clinical data was from 
medical records and was used to conduct a retrospective study. 
Study methods
Subject gender, age, body mass index (BMI), duration of dia-
betes, cardiovascular disease history, diabetes treatment meth-
od, and the number of blood pressure control drugs used were 
analyzed, and the measured glycated hemoglobin (HbA1c), 
blood pressure, and lipid conditions were examined in the ini-
tial and most recent visits, based on these results each goal was 
investigated after one year. High blood pressure patients were 
defined as drug therapy recipients with a blood pressure ≥130/ 
80 mm Hg, hyperlipidemia was defined as total cholesterol 
≥200 mg/dL, low density lipoprotein cholesterol (LDL-C) was 
defined at levels ≥100 mg/dL, high density lipoprotein choles-
terol (HDL-C) in men was defined as a level ≤40 mg/dL, and 
in women as a level ≤50 mg/dL in patients receiving drug 
treatment. Additionally, regardless of the number of visits to 
the outpatient clinic, in order to compare the indicators from 
the 135 (67.5%) patients who were followed for two years, the 
success percentage was investigated each year. Height and 
weight were measured directly by trained nurses after patients 
disrobed and removed their shoes, and BMI was calculated 
during the hospital visit by dividing the measured weight (kg) 
by the squared height (m
2). After allowing the blood pressure 
to stabilize for ten minutes, a mercury sphygmomanometer 
was used on the seated patients to measure their systolic and 
diastolic blood pressure. The diabetes treatment methods were 
separated into four parts: diet, oral hypoglycemic agents, insu-
lin monotreatment, insulin and oral hypoglycemic agents. Hy-
perglycemia management goals were HbA1c less than 7%, sys-
tolic blood pressure <130 mm Hg, and diastolic blood pressure 
<80 mm Hg. Total cholesterol less than 200 mg/dL, LDL-C 266
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less than 100 mg/dL, triglycerides less than 150 mg/dL, HDL-
C greater than 40 mg/dL in men, and over 50 mg/dL in wom-
en were set. In this study total cholesterol and HDL-C were 
measured using the enzymatic colorimetry test method, tri-
glycerides were measured using the glycerol elimination 
method, and LDL-C was measured using the homogenous en-
zymatic colorimetric test. Glycated hemoglobin was measured 
using high performance liquid chromatography (Tosoh, To-
kyo, Japan); the normal range in our hospital was 3.9% to 6.1%. 
During the initial patent visit, insulin was measured in 62.5% 
(125) patients, and C-peptide was measured in 70.5% (141) 
patients. Those figures could not be investigated one or two 
years later. The patient management goals were established in 
accordance with the guidelines of the American Diabetes As-
sociation [21]. Since this study was a retrospective study of 
routine medical care circumstances, the differences in patient 
compliance to treatment were objectified and, could not be 
stated clearly.
Statistical methods
All data was expressed as mean±standard deviation, and SPSS 
version 14.0 (SPSS Inc., Chicago, IL, USA) was used to perform 
all statistical analysis. The comparison among the blood glu-
cose, blood pressure, and lipid control groups, were analyzed 
using t-tests and chi-square tests; treatment success compari-
sons were analyzed using ANOVA repeated measurements with 
a significance level was set at P<0.05.
Diagnosis of metabolic syndrome
The National Cholesterol Education Program (NCEP)-ATP 
III criteria [22] were used to diagnose metabolic syndrome, 
and instead of measuring waist circumference, the World 
Health Organization (WHO) [23] criteria for BMI were in ad-
dition to the standard Asian obesity criteria, BMI ≥25 kg/m
2. 
Because this study is one among many studies on type 2 diabe-
tes patients, when the NCEP-ATP III diagnostic criteria [22] 
for hyperglycemia were assumed to be satisfied, and when more 
than two of other NCEP-ATP III criteria were met, patients 
were diagnosed with metabolic syndrome.
RESULTS
Patient characteristics
Among the 200 patients analyzed in this study, 106 were male, 
and 94 were female. The mean patient age was 56.0±11.3, and 
the mean BMI was 24.3±3.5 kg/m
2. Among the participants, 
43.0% were classified as obese, possessing a BMI greater than 
25 kg/m
2. Among the patients, 29.0% were first diagnosed 
with diabetes during this study, and 27.0% had been diagnosed 
with diabetes duration more than ten years prior. In addition 
45.0% of patients had been diagnosed with hypertension, 40.0% 
of patients had been diagnosed with hyperlipidemia, and 20.5% 
of patients had been diagnosed with both. Initially 30.0% of 
the patients did not have hypertension or hyperlipidemia and 
20.0% of patients had an HbA1c level greater than 10.0% at the 
first visit (Table 1). This study was conducted for one year by 
diabetes specialists on 200 patients who were receiving diabe-
tes treatment. After two years, 135 patients had been retained 
for follow up.
Blood glucose control
Of the original 135 patients who had followed-up, 51.8% had 
reached their goal of maintaining an HbA1c level less than 
7.0% after one year (Fig. 1), at which time, 25.5% of patients 
had the necessary glycated hemoglobin level needed to estab-
Table 1. Characteristics of the study subjects 
Characteristic  Total 
(n=200) 
Men 
(n=106)
Women 
(n=94)
Age, yr 56.0±11.3 54.3±11.4 58.0±11.0
BMI, kg/m
2 24.3±3.5 24.3±3.4 24.4±3.3
DM duration, yr 6.2±8.2 6.2±8.2 7.3±7.8
HbA1c, % 8.6±2.2 8.6±2.2 8.7±2.0
History of CVD, % 15 (n=30) 15 (n=16) 15 (n=14)
Blood pressure, mm Hg
Systolic 125.1±13.7 125.0±14.5 125.3±12.9
Diastolic 76.8±8.2 76.9±9.7 76.7±6.2
Total cholesterol,  
mg/dL
185.1±47.5 178.1±41.0 193.01±52.95
LDL-C, mg/dL 107.8±38.5 103.8±34.6 112.3±42.1
HDL-C, mg/dL 43.2±11.7 41.9±11.4 44.6±11.9
Triglyceride, mg/dL 147.6±91.9 150.6±85.8 144.2±98.6
Prevalence of  
hypertension, %
45 43.4 46.8
Prevalence of  
dyslipidemia, %
40 41.5 54.2
Data are presented as mean±standard error.
BMI, body mass index; DM, diabetes mellitus; CVD, cardiovascular 
disease; LDL-C, low density lipoprotein cholesterol; HDL, high den-
sity lipoprotein cholesterol. 267
The achievement of target goals in type 2 diabetic patients
Diabetes Metab J 2011;35:264-272 http://e-dmj.org
lish blood glucose control (greater than 8%). Among these pa-
tients, the percentage with glycated hemoglobin levels greater 
than 10% had increased to 7.5%. There were no differences in 
age and BMI based on analyzed results of patient characteris-
tics under the target 7% HbA1c. Among the 106 male partici-
pants, 62 (58.4%) reached their treatment goal, and among the 
94 female participants, 42 (44.6%) reached their treatment 
goal, demonstrating that male patients had a higher rate of 
success (P=0.035). Additionally, as glycated hemoglobin levels 
were lower initially, the treatment goal success rate increased 
(P<0.001). The average time since diagnosis of the patient 
group who reached their treatment goal was 4.6±7.1 years and 
the average time since diagnosis of the patient group who failed 
to reach their treatment goal was 8.0±8.9 years. The shorter 
was the time since diagnosis, the higher was the treatment 
success rate (P=0.003) (Table 2). In this study, diet, oral hypo-
glycemic agents, insulin monotherapy, and insulin and oral 
hypoglycemic agent combination therapy were divided into 
four groups, and the mean glycated hemoglobin levels of each 
group were compared. The mean level of the diet group was 
6.0±0.4%, that of the oral hypoglycemic agent group was 6.8± 
2.2%, that of the insulin monotherapy group was 7.9±2.5%, 
and that of the insulin and oral hypoglycemic agent combina-
tion therapy group was 8.3±4.1%. When the treatment meth-
ods of the 58 (29.0%) type 2 diabetes patients who were diag-
nosed with diabetes for the first time were examined, the re-
sults for diet, oral hypoglycemic agents, insulin monotherapy, 
and insulin and oral hypoglycemic agent combination therapy, 
were 1.7%, 69.0%, 15.5%, and 13.8%, respectively (Table 3).
Blood pressure control
Among the participants in this study, 45% (n=90) had hyper-
tension, and 32.2% of these patients had reached their treat-
ment goals after one year, and 64% of the participants were 
Table 2. Characteristics of the study subjects according to 
their achievement of glycemic control 
Characteristic 
HbA1c
P value
<7% ≥7%
Sex  Male 62 44 0.035
  Female 42 52
Age, yr 55.7±11.3 56.4±11.4 0.626
BMI, kg/m
2 23.9±3.0 24.7±3.9 0.295
Duration, yr 4.6±7.1 8.0±8.9 0.003
Initial HbA1c, % 7.8±2.2 9.7±1.8 <0.001
Data are presented as mean±standard error or number. 
BMI, body mass index.
Table 3. Diabetes management of study subjects with newly 
diagnosed diabetes 
Type of diabetes 
treatment No.(%) Antihyperten-
sive agent
Lipid lowering 
agent
Diet 1 (1.7) 1 (100.0) 1 (100.0)
OHA 40 (69.0) 19 (47.5) 20 (50.0)
Insulin 9 (15.5) 1 (11.1) 6 (66.7)
Insulin+OHA 8 (13.8) 2 (25.0) 2 (25.0)
Data are presented as number (%).
OHA, oral hypoglycemic agent.
Fig. 1. Proportion of patients reaching 
the therapeutic goals at baseline and 
one and two years later. Baseline in-
cludes only patients who were fol-
lowed-up until the end of the second 
year. BP, blood pressure; TC, total cho-
lesterol; LDL-C, low density lipoprotein 
cholesterol; TG, >triglyceride; HDL-C, 
high density lipoprotein cholesterol 
(HDL-C >40 mg/dL [male], HDL-C 
>50 mg/dL [female]). 
aP<0.001. 
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taking one type of antihypertensive drugs, 32% were taking 
two types of antihypertensive drugs, and 4% were taking three 
or more antihypertensive drugs. The percentage of treatment 
success in patients who were taking only one type of antihy-
pertensive drug was high. After one year, 32.2% of patients 
had reached their treatment goals. Among the 46 male partici-
pants, 11 (23.9%) reached their treatment goals, and among 
the 44 female participants, 18 (40.9%) reached their treatment 
goals. Females were more likely to achieve their treatment goals 
(P=0.025). In addition, success rates appeared to be indepen-
dent of age, BMI, HbA1c levels, and lipid treatment goals (Ta-
ble 4).
Lipid control
Initially, 40% (n=80) of the participants had dyslipidemia, and 
during the one year observation period, 7.5% (n=15) were 
newly diagnosed with dyslipidemia. The types of therapeutic 
drugs used to achieve lipid control were statin (n=67), fenofi-
brate (n=12), and statin and ezetimibe (n=1). Also, there were 
two cases in which treatment was changed from fenofibrate to 
statin during the observation period. In patients with dyslipid-
emia, the management goal success rate after one year was 
80% for total cholesterol (<200 mg/dL), while those of LDL-C 
(<100 mg/dL), triglycerides (<150 mg/dL), and HDL-C (>40 
mg/dL in males, >50 mg/dL) were 66.3%, 57.9%, and 51.8%, 
respectively. The percentage of patients who reached their se-
rum lipid level goals after one year were 78.0%, 63.0%, 67.0%, 
and 50% in each group, respectively. When the characteristics 
of the patients who had reached their treatment goals were ex-
amined, as age increased, success rate increased, and treatment 
goals were relatively unaffected by gender, BMI, and hyperten-
sion. The average HbA1c of patients who had reached their 
target was 6.8±1.0%, and the mean HbA1c of patients who had 
failed to reach their goal was 7.2±1.4%. The average HbA1c of 
patients who had reached their goal was lower than those who 
had failed to reach their goal, indicating that the number of 
patients who had good blood glucose or hyperlipidemia con-
trol was not statistically significant (P=0.197) (Table 4).
Annual follow-up results
Of the total 200 participants, 135 (67.5%) were followed-up 
for a two year period. Comparing the indicators of the 135 pa-
tients at the start of the treatment with those, one and two years 
after, the average HbA1c improved from 8.7±2.2% at the start 
of treatment to 7.2±1.5% after one year, and to 7.4±2.2% after 
two years (P<0.001) (Table 5). Compared to the changes in 
HbA1c, BMI, and systolic blood pressure showed no signifi-
cant changes, diastolic blood pressure, total cholesterol, and 
LDL-C were reduced, and HDL-C increased significantly. How-
ever, triglyceride levels increased in the 135 patients who un-
Table 4. Characteristics of study subjects according to their achievement of blood pressure and lipid control
Characteristic 
Blood pressure Lipid level
≥130/80 mm Hg <130/80 mm Hg P value Goal ( -) Goal ( +) P value
No. 61 29 66 29
Sex  Male 35 11 0.025 29 15 0.316
  Female 26 18 37 14
Age, yr 61.7±9.9 57.4±8.7 0.073 54.2±10.6 59.1±10.7 0.044
SBP, mm Hg 132.5±9.7 113.6±8.3 <0.001 122.2±12.5 123.8±12.1 0.272
DBP, mmHg 80.6±6.7 67.8±7.2 <0.001 73.1±9.3 75.7±7.5 0.572
HbA1c, % 7.2±1.4 7.5±1.5 0.407 7.2±1.4 6.8±1.0 0.197
BMI, kg/m
2 25.1±3.5 25.4±3.1. 0.647 25.5±2.7 25.9±3.0 0.526
Total cholesterol, mg/dL 172.7±31.9 168.9±37.6 0.259 176.4±41.1 154.7±21.7 0.009
Triglyceride, mg/dL 130.2±55.3 138.5±51.0 0.860 167.0±79.5 102.1±26.0 <0.001
HDL-C, mg/dL 43.3±8.8 45.4±11.0 0.228 43.3±9.3 51.9±7.3 <0.001
LDL-C, mg/dL 89.6±27.6 92.0±27.4 0.701 96.0±30.7 75.9±18.8 <0.001
Data are presented as mean±standard error or number. 
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol. 269
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derwent two years of follow-up (Table 5). Two years after the 
“3H care,” 57% of the 135 follow-up patients had reached their 
blood pressure goals, which was an improvement from that at 
the one year mark. The dyslipidemia success results showed 
that the cholesterol goal (<200 mg/dL) was achieved in 85.1% 
of patients and that for LDL-C (<100 mg/dL) was reached by 
71.8%. The percentages of patients achieving triglyceride 
(<150 mg/dL) and HDL-C goals were 64.5% and 64%, respec-
tively, and the two year follow-up showed a much higher 
achievement percentage than that at the one year follow up. 
The percentage of patients who had reached their goals for 
blood pressure and dyslipidemia were higher after two years 
than they were after one year, and patients who had reached 
their HbA1c goals were 51.8% after one year, and 43.7% after 
two years, showing a decreasing pattern. In addition, 4.4% 
(n=6) of patients had combination hyperglycemia, hyperten-
sion, and dyslipidemia after one year compared to 14.8% (n=
20) after two years (Fig. 1).
The prevalence and control of metabolic syndrome
Of the type 2 diabetes patients in this study, through 127 
(63.5%) were diagnosed with metabolic syndrome according 
to the NCEP-ATP III (using BMI instead of waist circumfer-
ence for diagnostic criteria). The prevalence of metabolic syn-
drome in males was 59.4% in male and 68.0% in females. When 
all patients were analyzed, the mean number of metabolic syn-
drome elements were 1.8±1.1, and only 12% of patients had 
only diabetes elements, while 25.5% had one element, 34.5% 
had two elements, 22.0% had three elements, and 6.0% had 
four elements. In patients with metabolic syndrome, the prev-
alence of each component of metabolic syndrome was: 49.5% 
for hypertension, 37.5% for hypertriglyceridemia, 56.0% for 
low HDL-C hyperlipidemia, 43.0% for Obese. Low HDL-C 
hyperlipidemia was the most common element of metabolic 
syndrome. Hypertension and hypertriglyceridemia were more 
prevalent in male patients, and low HDL-C hyperlipidemia 
had a higher prevalence in females. There was no difference in 
HbA1c level between the two groups based on the presence of 
metabolic syndrome. The prevalence of metabolic syndrome 
based on the duration of diabetes showed that prevalence in-
creased with duration, although the association was not statis-
tically significant. After one year, the HbA1c levels in the met-
abolic syndrome group and non-metabolic syndrome group 
were reduced from 8.6±1.8% to 7.4±1.4%, and from 8.6±2.7% 
to 7.1±1.8%, respectively. Blood pressure, triglyceride level, 
total cholesterol, and LDL-C were all reduced but HDL-C 
showed no change in the metabolic syndrome group. In the 
non-metabolic syndrome group, LDL-C was reduced or showed 
no significant change, and the triglyceride level increased 
(P<0.001).
DISCUSSION
Due to the increase in blood glucose levels and cardiometa-
bolic risk factors in type 2 diabetes patients, the risk of devel-
oping microvascular and macrovascular complications tend to 
increase. To prevent complications from diabetes in addition 
to blood glucose control, the importance of the management 
of cardiometabolic risk factors such as dyslipidemia and hy-
pertension has been emphasized. However, there are not many 
studies on how well it has actually been managed, and several 
studies have reported that actual medical care goal percentages 
could not be satisfied. In this study, 51.8% of patients reached 
their HbA1c goal of less than 7.0%, a lower number than was 
expected. When this study was compared with studies from 
other countries, the results reported by Harris et al. [24] showed 
that 44.6% of patients had reached the target of and HbA1c 
less than 7.0%. In the American National Health and Nutri-
tion Examination Survey (NHANES) [25], 57.1% of patients 
had reached the target HbA1c of less than 7.0%. In a reports 
by Liebl et al. [26] involving data from eight countries based 
on the European Diabetes Policy Group Guidelines, 31% had 
an HbA1c less than 6.5% and in reports by Sone et al. [27] from 
Table 5. Therapeutic target achievement at baseline and one 
and two years later 
 Variable Baseline 1 year later 2 years later
HbA1c, % 8.7±2.2 7.2±1.5
 a 7.4±2.2
 a
SBP, mm Hg 123.0±19.0 121.0±15.2 122.4±17.7
DBP, mm Hg 76.2±10.4 74.0±10.3 71.3±11.7
 a
BMI, kg/m
2 24.3±3.5 24.7±3.3 24.6±3.3
Total cholesterol, mg/dL 178.6±47.1 168.6±37.6 169.0±33.8
Triglyceride, mg/dL 142.3±93.3 140.1±81.0 154.3±149.3
HDL-C, mg/dL 42.9±11.0 44.7±10.4 49.1±11.2
 a
LDL-C, mg/dL 105.1±38.7 88.6±28.0
 a 85.2±11.2
 a
Data are presented as mean±standard error.
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, 
body mass index; HDL-C, high density lipoprotein cholesterol: LDL, 
low density lipoprotein cholesterol. 
aP<0.05 compared to the group of baseline.270
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Japan, 29.3% had an HbA1c less than 7.0%. In a South Korean 
study performed by Park et al. [17], 35.7% of patients reached 
their goal of an HbA1c less than 7.0%, and Lee et al. [28] re-
ported a success rate of 49.2%. These results were similar to or 
lower than the results in the presenting study.
  When the characteristics of patients who had reached their 
target for glycemic control and patients who had not reached 
their target for glycemic control were compared, the target 
success rate in males in this study was high, unlike that report-
ed by Lee et al. [28], while other studies have shown no differ-
ences between men and women, regarding increases in BMI 
or increasing effect of smoking on HbA1c [17,25-27]. Despite 
strict intensive care, HbA1c increased over time, in a previous 
study [8]. In the present study, the mean duration of diabetes 
in patients who successfully reached their treatment goals was 
4.6±7.1 years, and the mean duration in patients who did not 
reached their treatment goal was 8.0±8.9 years. The shorter 
was the duration of diabetes, the higher was the treatment suc-
cess rate (P=0.003) (Table 2).
  When the level of glycemic control based on diabetes treat-
ment was examined, the investigation of type 2 diabetes treat-
ment in the European CODE-II study [26] reported that the 
mean glycated hemoglobin levels of the diet and exercise, ad-
ministration of oral hypoglycemic agents, and insulin monotreat-
ment and insulin and hypoglycemic agent groups were 6.7%, 
7.5%, and 8.1%, respectively. In the present study, diet, oral 
hypoglycemic agents, insulin monotherapy, and insulin and 
oral hypoglycemic agent combination therapy were consid-
ered as four individual trait groups. When the mean glycated 
hemoglobin values of each was compared, the results showed 
that the diet group had a value of 6.0±0.4%, that of the oral 
hypoglycemic agents group was 6.8±2.2%, that of the insulin 
monotherapy group was 7.9±2.5%, and that of the insulin and 
oral hypoglycemic agents combination therapy group was 
8.3±4.1%. Glycemic control becomes more difficult as diabe-
tes progresses, and the necessity for additional drug actions 
can be seen. Of the total participants 45% (n=90) had hyper-
tension, and similarly, 20% to 60% of patients had diabetes 
with hypertension. In the one year follow-up focused on target 
success among hypertension patients, 32.2% reached their tar-
get. In the reports of the tertiary hospital-based study of Lim 
et al. [13], 43.2% of patients who had taken antihypertensive 
drugs had a blood pressure below the target 130/85 mm Hg, a 
lower than expected result which prompted consideration of 
target lower in. In the present study 44.5% of all patients had 
under 130/80 mm Hg, which was similar to the 45.5% report-
ed by the NHANES. When the two year follow-up results were 
examined, 57% of patients had achieved their two year “3H 
care.” These results were compared with the one year follow-
up results, to determine whether a higher success rate had 
been achieved, based on management efforts and demonstrat-
ed that the target blood pressure was more achievable.
  In patients with dyslipidemia, after one year of management, 
the success rate for total cholesterol in patients was 80%, and 
those of LDL-C, triglycerides, HDL-C were 66.3%, 57.9%, and 
51.8%, respectively. These results were higher than the 56.6% 
for total cholesterol and 35.7% for LDL-C reported by Lim et 
al. [13] in their study on dyslipidemia patients at a tertiary 
hospital. After one year, the plasma lipid levels in all patient 
groups were 78.0%, 63.0%, 67.0%, and 50.0%, respectively, 
which were higher than that reported by the NHANES [25]: 
46.5% LDL-C, 46.6% triglycerides, and 58.0% HDL-C. The 
LDL-C success rate in our study was also greater than that of 
the NHANES, which was 51.0%. Due to the nature of the par-
ticipants in the present study, the use of aggressive lipid-lower-
ing drugs and appropriate monitoring devices from the diabe-
tes clinic specialist is believed to have contributed to this suc-
cess rate. Despite undergoing aggressive drug therapies for hy-
perglycemia, hypertension, and dyslipidemia during the two 
year experimental period, the final results are not significantly 
different from the reports after one year of treatment. There-
fore, after a maximum of one year of close observation, the in-
troduction of more aggressive therapy is thought to be neces-
sary for patients who are unable to reach their targets. In addi-
tion, the success rate of hypertension, dyslipidemia, and high 
blood sugar treatments was only 4.4% (n=6) after one year, 
and 14.8% (n=20) after two years. In order to reduce mortality 
from microvascular and macrovascular complications, these 
three conditions must be simultaneously managed, and to 
achieve target levels, various treatment may be necessary. Ad-
ditionally, 32.5% (n=65) of the original participants in this 
study did not finish the study, which was similar to the drop-
out rate from another studies [27]. Such high dropout rates 
make continuous integrated treatments impossible, and since 
this deteriorates the quality of diabetes management, encour-
aging patients to continue with their treatment is important.
  The components of metabolic syndrome typically accom-
pany type 2 diabetes, which is clinically important due to the 
increased risk of cardiovascular disease in patients with diabe-
tes [18-20]. The prevalence of metabolic syndrome in the par-271
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ticipants of this study was 63.5%, lower than the 82.6% found 
using the International Diabetes Federation (IDF) criteria in 
German type 2 diabetes patients [29] and that of the preva-
lence of metabolic syndrome in diabetes patients older than 50 
years from the NHANES [25], and similar to the 65.9% preva-
lence of metabolic syndrome in Hong Kong diabetes patients 
[30]. In a study performed in 2006 by Kim et al. [31] on Kore-
an metabolic syndrome patients, the prevalence of metabolic 
syndrome in type 2 diabetes patients was 77.9%, which was 
higher than what was reported by the present study. Tong et al. 
[30] reported that diabetes patients with metabolic syndrome 
are more at risk for cardiovascular disease than diabetes pa-
tients without metabolic syndrome. Therefore, identifying the 
presence of metabolic syndrome in type 2 diabetes patients is 
an important step in treatment. 
  There were several limitations in this study. This study was 
performed at one center and the study did not include a large 
variety or a large number of patients. In addition in the two 
year follow-up, 65 patients dropped out and their data could 
not be used. Therefore, in the future, a larger scale study will 
be required to establish the success rates and complications of 
metabolic syndrome in type 2 diabetes patients. In conclusion, 
this study showed the current situation of type 2 diabetes pa-
tients who are receiving treatment from endocrinologists at a 
single university hospital, and the results of the one year of 
“3H care” show that 48.2% of cases with hyperglycemia, 55.5% 
of cases with hypertension, and 32% to 50% of cases with dys-
lipidemia had not reached their targets. The results from two 
years of “3H care” yielded similar results. The results were slight-
ly improved compared to those of several previous studies 
however, the improvement did not reach a satisfactory level. 
Also, more research and clinical effort will be requied to achieve 
the targets of hyperglycemia, hypertension, and dyslipidemia.
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